CODE BIOTHERAPEUTICS
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.
CODE BIOTHERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Life Science
Founded:
2020-01-01
Address:
Hatfield, Pennsylvania, United States
Country:
United States
Website Url:
http://www.codebiotx.com
Total Employee:
11+
Status:
Active
Contact:
215-996-3006
Total Funding:
85 M USD
Similar Organizations
Atalanta Therapeutics
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.
Axcella
Axcella is a biotechnology company providing therapeutics development solutions.
Black Diamond Therapeutics
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Voyager Therapeutics
Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system
Current Advisors List
Current Employees Featured
Founder
Investors List
UPMC Enterprises
UPMC Enterprises investment in Series A - Code Biotherapeutics
Amgen Ventures
Amgen Ventures investment in Series A - Code Biotherapeutics
CureDuchenne Ventures
CureDuchenne Ventures investment in Series A - Code Biotherapeutics
New Enterprise Associates
New Enterprise Associates investment in Series A - Code Biotherapeutics
4BIO Capital
4BIO Capital investment in Series A - Code Biotherapeutics
UCB Ventures
UCB Ventures investment in Series A - Code Biotherapeutics
Takeda Ventures
Takeda Ventures investment in Series A - Code Biotherapeutics
JDRF T1D Fund
JDRF T1D Fund investment in Series A - Code Biotherapeutics
Northpond Ventures
Northpond Ventures investment in Series A - Code Biotherapeutics
Hatteras Venture Partners
Hatteras Venture Partners investment in Series A - Code Biotherapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-02 | Code Biotherapeutics Appoints Erin Brubaker as Chief Operating Officer |
Official Site Inspections
http://www.codebiotx.com Semrush global rank: 7.76 M Semrush visits lastest month: 437
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
